Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Clinical COPD phenotypes identified by cluster analysis: validation with mortality

Pierre-Régis Burgel, Nicolas Roche, Jean-Louis Paillasseur, Isabelle Tillie-Leblond, Pascal Chanez, Roger Escamilla, Isabelle Court-Fortune, Thierry Perez, Philippe Carré, Denis Caillaud on behalf of the INITIATIVES BPCO scientific committee
European Respiratory Journal 2012 40: 495-496; DOI: 10.1183/09031936.00228511
Pierre-Régis Burgel
*Service de Pneumologie, Hôpital Cochin, AP-HP and Paris Descartes University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pierre-regis.burgel@cch.aphp.fr
Nicolas Roche
#Service de Pneumologie, Hôpital de l'Hôtel Dieu, AP-HP and Paris Descartes University, Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Louis Paillasseur
¶Clindatafirst, St Quentin en Yvelines
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Tillie-Leblond
+Service de Pneumologie, Hôpital Calmette, Lille
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Chanez
§Dépt des Maladies Respiratoires, AP-HM, Université de la Méditerranée, Marseille
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Escamilla
fClinique des voies respiratoires Hopital Larrey, Toulouse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Court-Fortune
**Service de Pneumologie, CHU Saint Etienne, Saint Etienne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Perez
+Service de Pneumologie, Hôpital Calmette, Lille
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Carré
¶¶Service de Pneumologie, Hôpital Gabriel Montpied, CHU Clermont-Ferrand, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Caillaud
¶¶Service de Pneumologie, Hôpital Gabriel Montpied, CHU Clermont-Ferrand, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Because forced expiratory volume in 1 s is a poor descriptor of chronic obstructive pulmonary disease (COPD) heterogeneity [1], interest has emerged regarding the identification of clinically relevant COPD phenotypes [2, 3]. We recently reported the usefulness of applying mathematical models (i.e. principal component and cluster analyses) to multiple variables for the identification of clinical phenotypes in a cohort of COPD subjects [4]. These original analyses allowed the description of four COPD groups, which we called “clinical COPD phenotypes” [4]. This terminology was based on the classical definition of “phenotype”, referring to the observable characteristics (including respiratory manifestations and comorbidities) of patients. Recently, a panel of experts proposed the following modified definition for clinical COPD phenotypes: “a single or combination of disease attributes that describes differences between individuals with COPD as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death)” [2, 3]. These authors suggested that, before being referred to as clinical phenotypes, clusters of related patients require longitudinal validation to determine how they differ with respect to important clinical outcomes [2].

Here we report on the longitudinal follow-up of the 322 COPD subjects included in our previous study [4]. The vital status of these subjects was systematically requested on June 19, 2009. Data were obtained for 303 (94.1%) out of the 322 subjects and the median (interquartile range) follow-up duration, which was not significantly different across phenotypes (unpublished data) was 3.35 (2.01–4.25) yrs. During follow-up, 60 (19.8%) out of 303 subjects died and crude mortality rates were as follows: 15 (35%) out of 43 subjects for phenotype 1; seven (8%) out of 88 subjects for phenotype 2; 17 (20%) out of 87 subjects for phenotype 3; and 21 (25%) out of 85 subjects for phenotype 4. Kaplan–Meier analysis of survival by phenotype is presented in figure 1. Subjects in phenotype 2 (older age, mild-to-moderate airflow obstruction and low rates of comorbidities) had a lower mortality, but no significant survival difference was found between phenotypes 1, 3 and 4. Because subjects belonging to various phenotypes had marked differences in age at inclusion (median age 58–73 yrs) and because the observation period was relatively short, we hypothesised that age of death would be different among the phenotypes. Indeed, median (interquartile range) age of death was: 62 (58–68) yrs for phenotype 1; 77 (66–83) yrs for phenotype 2; 67 (58–69) yrs for phenotype 3; and 76 (74–79) yrs for phenotype 4. Based on these findings, we analysed mortality risks among phenotypes using Cox models (both unadjusted and adjusted for age) (fig. 2). The unadjusted model confirmed that phenotypes 1, 3 and 4 had a statistically significant two- to four-fold increase in mortality risk when compared with phenotype 2. In the model adjusted for age, phenotype 1 also had a statistically significant increase in mortality risk compared with phenotype 4 (OR 3.18, 95% CI 1.37–7.40; p=0.007), and a trend towards increased mortality risk compared with phenotype 3 was also observed (OR 1.91, 95% CI 0.94–3.06; p=0.07). However, this trend did not reach statistical significance, probably due to the limited numbers of patients within these phenotypes. No significant difference in mortality risks were observed between phenotype 3 and phenotype 4.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Kaplan–Meier analysis of mortality among phenotypes (phen). Subjects in phenotype 2 had the lowest mortality rates (log-rank test with Tukey–Kramer adjustment for multiple comparisons): phenotype 2 versus phenotype 1, p=0.003; phenotype 2 versus phenotype 4, p=0.03; phenotype 2 versus phenotype 3, p=0.17. However, no significant difference was observed between the other phenotypes, indicating comparable mortality rates during the (relatively short) follow-up period.

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Mortality risks in 303 chronic obstructive pulmonary disease subjects with phenotypes and age as covariates. a) Cox model unadjusted for age. b) Cox model adjusted for age. Horizontal bars show odds ratios (OR) and 95% confidence intervals (CIs) of mortality risks between phenotypes. For example, in the model adjusted for age, subjects in phenotype 1 have an 8.5-fold (95% CI 3.13–22.22, p<0.001) increased risk of mortality when compared with subjects in phenotype 2.

In conclusion, the longitudinal follow-up identified phenotype 2 as a phenotype with a very low risk of mortality. Additionally, subjects in phenotype 1 (younger subjects with severe airflow limitation, repeated exacerbations, low body mass index and low rates of cardiovascular comorbidities) had the greatest mortality rates and died at a younger age. Thus, these phenotypes actually meet the criteria required to define “clinical phenotypes”. Differences in mortality between phenotypes might be even more pronounced over a longer term, but this will have to be confirmed by further survival analyses of the cohort.

Footnotes

  • Support Statement

    This work was funded by unrestricted grants from Boehringer Ingelheim and Pfizer (both Paris, France).

  • Statement of Interest

    A statement of interest for this study can be found at www.erj.ersjournals.com/site/misc/statements.xhtm

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Agusti A,
    2. Calverley PM,
    3. Celli B,
    4. et al
    . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
    OpenUrlPubMed
  2. ↵
    1. Han MK,
    2. Agusti A,
    3. Calverley PM,
    4. et al
    . Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Agusti A,
    2. Celli B
    . Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J 2011; 38: 749–751.
    OpenUrlFREE Full Text
  4. ↵
    1. Burgel PR,
    2. Paillasseur JL,
    3. Caillaud D,
    4. et al
    . Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531–539.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 2 Table of Contents
European Respiratory Journal: 40 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical COPD phenotypes identified by cluster analysis: validation with mortality
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Clinical COPD phenotypes identified by cluster analysis: validation with mortality
Pierre-Régis Burgel, Nicolas Roche, Jean-Louis Paillasseur, Isabelle Tillie-Leblond, Pascal Chanez, Roger Escamilla, Isabelle Court-Fortune, Thierry Perez, Philippe Carré, Denis Caillaud
European Respiratory Journal Aug 2012, 40 (2) 495-496; DOI: 10.1183/09031936.00228511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clinical COPD phenotypes identified by cluster analysis: validation with mortality
Pierre-Régis Burgel, Nicolas Roche, Jean-Louis Paillasseur, Isabelle Tillie-Leblond, Pascal Chanez, Roger Escamilla, Isabelle Court-Fortune, Thierry Perez, Philippe Carré, Denis Caillaud
European Respiratory Journal Aug 2012, 40 (2) 495-496; DOI: 10.1183/09031936.00228511
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • How can we achieve better prevention of TB among contacts?
  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society